Kiwi Biosciences
Kiwi Bio: Developing enzymes to ease digestion for IBS sufferers.
Kiwi Bio: Developing enzymes to ease digestion for IBS sufferers.
Kiwi Biosciences, founded with a mission to improve the quality of life for individuals suffering from Irritable Bowel Syndrome (IBS), focuses on developing novel, patent-pending enzymes that break down common digestive triggers in food. Their flagship product, FODZYME®, is specifically designed to help people digest foods high in FODMAPs, which are often problematic for IBS sufferers. Kiwi Biosciences aims to alleviate digestive discomfort and enable individuals to enjoy a wider variety of foods without adverse effects.
Notable figures affiliated with Kiwi Biosciences include experts in biotechnology and gastroenterology, though specific names are not provided. The company has garnered attention for its innovative approach to digestive health and its potential to impact the lives of approximately 18 million Americans with IBS. Key achievements include the successful development and commercialization of FODZYME®, available in various kits for home and on-the-go use. Kiwi Biosciences' work represents a significant advancement in the management of dietary triggers for IBS, offering a practical solution for improved digestive health.
Companies similar to Kiwi Biosciences include Fzata, ZBiotics, Intact Therapeutics and EnzymeBioSystems.
Kiwi Biosciences was founded in 2020.
Kiwi Biosciences' headquarters is located in Cambridge, MA, US.
Kiwi Biosciences' most recent funding round was for $1.5M (USD) in October 2021.
As of Oct 14, 2021, Kiwi Biosciences has disclosed funding of $1.6M (USD). Undisclosed round amounts are excluded.
Kiwi Biosciences has 9 employees as of Feb 4, 2024.
EnzymeBioSystems
